Affinor Resources Inc.

Affinor Resources Inc.

April 01, 2014 14:32 ET

Drug Development Expert From National Research Council Canada, Sazzad Hossain, PhD Joins the Affinor Resources Advisory Board

MONTREAL, QUEBEC--(Marketwired - April 1, 2014) -

Sebastien Plouffe reports

Affinor Resources (CSE:AFI) announces the addition of Senior Scientist from the NATIONAL RESEARCH COUNCIL CANADA - GOVERNMENT OF CANADA, Sazzad Hossain, PhD to it's advisory board.

Dr. Sazzad has more than 20 years of academic and industrial experience in new drug discovery, natural health product development. He was Group Leader and Senior Scientist at Biotechnology Research Institute of National Research Council Canada, Government of Canada's prime biotechnology research organization where he set up pharmacology laboratory to evaluate safety and efficacy of new drugs under development in the areas of cancer, cardiovascular and ocular diseases. Prior to joining the National Research Council Canada, he was at Xenon Pharmaceuticals in Vancouver, B.C, where he was Associate Director of Pharmacology and led pharmacology teams targeting pain, inflammation and cardiovascular diseases. Sazzad received his PhD in Biology from Moscow State Academy of Veterinary Medicine & Biotechnology and received post-doctoral training in the Department of Nutritional Science and Department of Medical Genetics of University of British Columbia. He was associate professor of pharmacology at Federal University of Minas Gerais, Brazil between 1988 -1996. He is the author of more than 40 peer-reviewed papers, primarily in the pharmacology, genetics and nutritional sciences. The company has granted 100,000 incentive stock options to Dr. Sazzad to purchase common shares of the company. The options are exercisable on or before April 1st, 2019, at an exercise price of $0.25 per share.

Sebastien Plouffe, President and CEO of Affinor Resources comments: "I am very pleased to the great addition of Dr. Sazzad Hossain, PhD to our advisory board. His scientific skills and connections both with in government and the private sectors, will be of paramount importance in Affinor's move to becoming a premier Canadian Medical Marijuana producer."

About Affinor Resources Inc.

Affinor Resources is a diversified publicly traded company on the Canadian Securities Exchange under the symbol ("AFI"). Affinor is focused on the Medical Marijuana industry within North America as well as Affinor has a Mineral Exploration division. Affinor is currently working towards becoming a premier Canadian Medical Marijuana and Industrial Hemp company by consolidating fragmented medical marijuana grower facilities and bringing industry expertise to its advisory board.

On Behalf of the Board of Directors


"Sebastien Plouffe"

President & CEO


This News Release contains forward-looking statements. The use of any of the words "anticipate", "continue", "estimate", "expect", "may", "will", "project", "should", "believe" and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this News Release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company's disclosure documents which can be found under the Company's profile on This News Release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release

Contact Information